

## Correction to: Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers

Lesley J. Scott<sup>1</sup>

Published online: 4 May 2018  
© Springer International Publishing AG, part of Springer Nature 2018

### Correction to: Drugs

<https://doi.org/10.1007/s40265-018-0903-9>

An Online First version of this article was made available online at <http://link.springer.com/journal/40265/onlineFirst/page/1> on 16 April 2018. Errors were subsequently identified in the article, and the following corrections should be noted:

- **Rewording in main text**

**Section 1, Introduction, paragraph 3, line 1:** The following line, which previously read:

“Apatinib [AiTan<sup>TM</sup> (China); Rivoceranib® (global)] is a”

Should read:

“Apatinib [Aitan® (brand name in China)], also known as rivoceranib, is a”

The original article has been updated.

---

The original article can be found online at <https://doi.org/10.1007/s40265-018-0903-9>.

---

✉ Lesley J. Scott  
demail@springer.com

<sup>1</sup> Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand